Study of TRB-001 vaccine for Parkinson's disease after prior immunotherapy
Part of Brain & nervous system clinical trials.
This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Participants must be 18 years of age or older.
- Participants must have a diagnosis of Parkinson's disease (any stage).
- Participants must have previously received immunotherapy targeting alpha-synuclein.
- Participants must not be pregnant, breastfeeding, or of childbearing potential without using contraception.
- Participants must not have contraindications to MRI or lumbar puncture.
- Participants must not have autoimmune disease, active infections (hepatitis B/C, HIV), recent cancer, substance abuse, or unstable psychiatric conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3962681 in two groups: healthy volunteers and people with Parkinson's disease. The goal is to see if the drug is safe and how the body handles it, which may lead to future treatments for Parkinson's.
This study tests an investigational drug called MT101-5 for people with early Parkinson's disease. The goal is to see if it is safe and can help slow the progression of symptoms.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
This study tests a new investigational vaccine called TRB-001 for people with early Parkinson's disease. It looks at whether the vaccine is safe and whether it can help the immune system fight the disease.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.